Bioventus sees FY25 revenue $560M-$570M, consensus $554.78M

Bioventus (BVS) introduced its financial guidance for full-year 2025. The Company expects: Net sales of $560 million to $570 million. This reflects organic growth of approximately 6.1% to 8.0% when including the impact of the Company’s divestiture of its Advanced Rehabilitation Business, which generated revenue of $45.4 million in 2024. Adjusted EBITDA of $112 million to $116 million, reflecting 100 basis points in Adjusted EBITDA Margin growth compared to the 2024 Adjusted EBITDA Margin of 19.0% when using the low end of the 2025 revenue and Adjusted EBITDA guidance. Non-GAAP EPS of $0.64 to $0.68, reflecting an increase of 30.6% to 38.8%, consensus 55c.